Phase 1 N=9 Study of Proton Therapy in Adjuvant Pancreatic Cancer
Resected Pancreatic Adenocarcinoma
Primary: Incidence of Dose Limiting Toxicites (DLTs) — 0; 1 Dose limiting Toxicities
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=9 FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
Acute Myeloid Leukemia · Myeloid Leukemia · Monocytic Leukemia
Primary: Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events — 0; 0; 0; 0 Count of Participants
Phase 1 N=41 A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Soft Tissue Sarcoma
Primary: Number of Participants With Olaratumab Dose Limiting Toxicities (DLTs) — 0; 0; 0 participants
Phase 1 N=39 A Social Network AOD Intervention for Homeless Youth Transitioning to Housing
Substance Use
Primary: Number of Days Cannabis Used — 23.7; 7.36 days
Phase 1 N=1 Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia
Acute Myeloid Leukemia
Primary: Incidence of Adverse Events — 1; 1; 1; 1 participants
Phase 1 N=79 Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)
Respiratory Syncytial Virus (RSV)
Primary: Area Under the Curve (AUC) for RSV-A Memphis 37b Viral Load Determined by Quantitative Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) — 350.99…
Phase 1 N=12 TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)
Multiple Myeloma, Relapsed · Multiple Myeloma, Refractory to Standard Treatment
Primary: Maximum Tolerated Dose (MTD) of Gy — NA Participants
Phase 1 N=51 Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis and CVD Risk
Postmenopausal Osteoporosis · Gut Microbiota · Cardiovascular Diseases
Primary: Bone Mineral Density (BMD) — 1.14; 1.15; 1.17; 1.14 g/cm^2
Phase 1 N=12 Safety Study of Gene Therapy in Treating Critical Leg Ischemia
Critical Limb Ischemia
Primary: Treatment-Emergent Adverse Events. — 3; 3; 3; 3 Participants
Phase 1 N=60 AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19
COVID-19
Primary: Number of Participants With Adverse Events (AEs) and Serious AEs — 8; 2; 5; 6 Participants
Phase 1 N=15 A Phase I Study of TAS-102 in Solid Tumors
Advanced or Metastatic Solid Tumors
Primary: Cmax (Maximum Plasma Concentration) of FTD — 3019.49; 3693.08 ng/mL
Phase 1 N=12 MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)
End-Stage Renal Disease · Kidney Failure, Chronic
Primary: Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE) — 0 Participants
Phase 1 N=112 Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
Actinic Keratosis · Keratosis, Actinic · Keratosis
Primary: Frequency and Severity of Adverse Events (AEs), Serious AEs (SAEs), and Treatment Emergent Adverse Events (TEAEs). — 888; 563; 242; 83 Number of events
Phase 1 N=59 A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533.
Malaria
Primary: The Tolerability and Safety of Ascending Single Oral Doses of MMV533 — 5; 3; 7; 4 participants
Phase 1 N=68 Clinical Trial of HIV Vaccine Combinations in Healthy Men and Women
Human Immunodeficiency Virus
Primary: Number of Participants With Mucosal Binding IgG Antibodies to HIV CN54gp140 Antigen — 0; 3; 1; 6 Participants